UCB SA (UCB.BR)

120,85 -0,90 (-0,74%) In data: 05:20PM CEST. Mercato aperto.

UCB SA

Allée de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 8.450

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Jean-Christophe Tellier	CEO & Executive Director	4,1M	N/D	1959
Ms. Sandrine Dufour CFA	Executive VP, CFO & Chief Corporate Development	N/D	N/D	1966
Dr. Kirsten Lund-Jurgensen Ph.D.	Executive Vice President of Supply & Technology Solutions	N/D	N/D	1960
Dr. Dhavalkumar D. Patel M.D., Ph.D.	Executive VP & Chief Scientific Officer	N/D	N/D	1961
Ms. Denelle J. Waynick Johnson J.D.	Executive VP & General Counsel	N/D	N/D	1967
Mr. Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	N/D	N/D	1965
Prof. Iris Low-Friedrich	Executive VP & Chief Medical Officer	N/D	N/D	1960
Mr. Emmanuel Caeymaex	Executive VP of Immunology Solutions & Head of US	N/D	N/D	1969
Ms. Caroline Vancoillie	Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions	N/D	N/D	N/D
Antje Witte	Head of Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Governance aziendale

L'ISS Governance QualityScore di UCB SA al 1 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 1; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.